|Last Price||Today's Change||52-Week Range||Trading Volume|
|18.19||-0.18 (-0.98%)||15.19 - 20.24||2.0 thousand (Below Avg)|
Market data as of 10:39AM 12/11/13. Quotes are delayed by at least 15 min.
Phase 3 Data Show Daiichi Sankyo's Once-Daily Edoxaban Lowered Incidence of VTE Recurrence and Clinically Relevant Bleeding Compared to Warfarin in a Large Subgroup of Patients with Cancer
12/09/2013 8:05 AM ET
Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
11/19/2013 11:50 AM ET